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Host defense peptides (HDPs) are an evolutionarily conserved component of the innate
immune response found in all living species. They possess antimicrobial activities against a
broad range of organisms including bacteria, fungi, eukaryotic parasites, and viruses. HDPs
also have the ability to enhance immune responses by acting as immunomodulators.
We discovered a new family of HDPs derived from pathogenic helminth (worms) that
cause enormous disease in animals and humans worldwide. The discovery of these
peptides was based on their similar biochemical and functional characteristics to the
human defense peptide LL-37. We propose that these new peptides modulate the immune
response via molecular mimicry of mammalian HDPs thus providing a mechanism behind
the anti-inflammatory properties of helminth infections.
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INTRODUCTION
Host defense peptides (HDPs) are conserved in all living species as
a primitive component of the innate immune response (Hancock
and Diamond, 2000; Bowdish et al., 2004) and have a broad-
spectrum of activity against bacteria, fungi, eukaryotic parasites,
and viruses (Mookherjee and Hancock, 2007; Andes et al., 2009;
Hsu et al., 2009). The abilities of HDPs to suppress infections are
mediated by direct antimicrobial properties, modulation of host
immune responses, or both (Bommarius et al., 2010). Initially
called antimicrobial peptides (AMPs) because of their capacity of
directly killing microbes, these peptides are now referred as HDPs
due to their added immunomodulatory properties (Hancock and
Sahl, 2006).
Helminths comprise a variety of parasitic worms, includ-
ing nematodes, cestodes and trematodes. We discovered a novel
family of HDPs derived from pathogenic trematodes including
Fasciola, Schistosoma, Opisthorcis, Paragonimus, and Clonorchis
species that cause enormous disease in animals and humans in
many parts of the world, particularly in poorer regions. We char-
acterized them as HDPs based on their similar biochemical and
functional characteristics to human defense peptides, particularly
LL-37 (Robinson et al., 2011). We suggested that these new pep-
tides modulate the immune response via molecular mimicry of
HDPs thus providing a mechanism for the anti-inflammatory
properties commonly observed in these helminth infections.
STRUCTURAL CHARACTERISTICS AND PROPERTIES OF HDPs
HDPs are defined as short peptides of 12–50 amino acids with
an overall positive charge of +2 to +9 due to the predomi-
nance of basic amino acids (arginine, lysine, and histidine) over
acidic amino acids (Hancock and Chapple, 1999). They also
have the property of folding into amphipathic structures where
the charged and hydrophilic portions are segregated from the
hydrophobic portions. In general, at least 50% of the amino
acids are hydrophobic, allowing interaction with bacterial mem-
branes as a part of HDP mechanism of action (Hancock and
Chapple, 1999). In aqueous solution, HDPs remain unstructured
but adopt the amphipathic structure upon interaction with mem-
branes (McPhee and Hancock, 2005), an attribute that may be
crucial for their activity and for reducing general cytotoxicity
(Kindrachuk et al., 2010). Despite their small size and common
physico-chemical features, HDPs are classified according to their
3-D structures.
In mammals, the two major families of HDPs include the
α- and β-defensins and the cathelicidin. The defensins are char-
acterized by a β-sheet globular structure stabilized by intramolec-
ular disulfide bridges. In human skin, defensins are principally
expressed by keratinocytes, neutrophils, and sudoriferous and
sebaceous glands (Koczulla and Bals, 2003) where they can be
produced constitutively or in response to an inflammatory stimu-
lus. Their expression was reported in other cell types such as tissue
macrophages, small intestinal epithelial cells as well as cardiomy-
ocytes. The second group is formed by the cathelicidins which
are distinguishable by their linear α-helical structure. All mem-
bers of the cathelicidin category contain a structurally variable
cationic C-terminal portion and a highly conserved N-terminal
cathelin domain that must be cleaved to release the active C-
terminal peptide (Ramanathan et al., 2002). Cathelicidins are
usually expressed by myeloid precursor cells but they are also
found in neonatal lymphoid tissue and in mature circulating neu-
trophils in some species (Zanetti, 2004). In humans, they are
produced in epithelial cells and in different tissues and corporal
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fluids like gastric juices, saliva, semen, sweat, plasma, airway sur-
face liquid, and breast milk (Bals et al., 1998; Murakami et al.,
2002; Hase et al., 2003). They are stored in their inactive forms
in specific granules and processed exclusively upon stimulation,
releasing the active HDPs into the extracellular fluid (Scott et al.,
2002; Zanetti, 2004).
The best-characterized cathelicidin is the human LL-37, a
cationic (+6) peptide of 37 residues with a molecular mass of
4.5 kDa. It adopts an amphipathic α-helix structure and possesses
a broad spectrum antimicrobial activity. This peptide is contained
within an inactive secreted precursor protein termed hCAP-18
(human cationic antimicrobial protein 18 kDa; the actual molec-
ular weight is 16 kDa) which is cleaved by endogenous serine pro-
teinase three to release the C-terminal active 37-residue peptide
(Agerberth et al., 1995; Gudmundsson et al., 1996). It is produced
by neutrophils, macrophages and mucosal epithelial cells upon
stimulation by microorganisms and pro-inflammatory media-
tors (Durr et al., 2006; Mookherjee et al., 2007). Upon injury or
infection, there is a strong up-regulation of hCAP-18/LL-37, sug-
gesting the involvement of LL-37 in assisting the immune system.
In contrast, several diseases have been associated with the down-
regulation of LL-37 such as chronic periodontal disease (Putsep
et al., 2002), atopic dermatitis (Ong et al., 2002), chronic ulcers
(Heilborn et al., 2003) and an increase of the risk for skin infec-
tions. LL-37 also plays a central role in innate immune responses
and inflammation. It is known as a potent chemoattractant for
mast cells (Niyonsaba et al., 2002), monocytes, T lymphocytes
and neutrophils (Yang et al., 2000) through the receptor FPRL1
(formyl peptide receptor-like 1). It promotes wound healing
(Heilborn et al., 2003) probably through re-epithelialization and
vascularization (Ramos et al., 2011), angiogenesis and arteriogen-
esis (Ramos et al., 2011) and acts as immune adjuvant (Kurosaka
et al., 2005). LL-37 is also known to bind to lipopolysaccharide
(LPS) and neutralize its biological actions by preventing its inter-
action with LPS-binding protein (Larrick et al., 1995; Kirikae
et al., 1998; Nagaoka et al., 2001).
BIOLOGICAL ACTIVITIES OF HDPs
The HDPs are multifunctional molecules involved in the direct
killing of microbes and in the mediation of various host
responses. It is well recognized that HDPs exhibit potent activity
against microbes as part of the innate immune system (Auvynet
and Rosenstein, 2009). Recent studies also evoke their importance
in the regulation of innate immune responses and in protecting
against the detrimental effects of an excessive innate inflam-
matory response (Tecle et al., 2007, 2010; Miles et al., 2009;
Murakami et al., 2009; Giuliani et al., 2010).
The antimicrobial activity of HDPs is driven by the charge. The
bacterial cell membranes are composed of a high proportion of
acidic phospholipids, conferring a negative charge to the surface
(Matsuzaki, 1999). The cationic nature of the HDPs is attracted
by electrostatic forces to the negative surface of the bacteria, facil-
itating the direct lysis of the cell through the permeabilization
of the membranes (Lehrer et al., 1993). The absence of choles-
terol in bacterial membranes also increases the activity of HDPs
(Zasloff, 2002). In contrast, the phospholipids in eukaryotic cell
membranes are predominantly sequestered in the inner leaflet
of the lipid bilayer, leaving the outer leaflet with no or little
net charge. Cholesterol is an essential lipid in the composition
of eukaryotic membranes, preventing membrane damage. These
elements explain why concentrations of HDPs found in vivo do
not cause host-damage (Boman, 2003). HDPs are usually secreted
as cocktails at the site of infection and/or inflammation and
act synergistically to increase their effectiveness of antimicro-
bial activity (Doss et al., 2010; Tecle et al., 2010). While several
models on how AMPs actually kill microbes have been proposed
(Bierbaum and Sahl, 1985; Westerhoff et al., 1989; Matsuzaki,
1999; Yang et al., 2000; Kragol et al., 2001; Brogden, 2005), direct
antimicrobial action is probably not the most important role of
HDPs since they present low antimicrobial activities under serum
and tissue conditions (Hancock and Diamond, 2000; Hancock,
2001). In fact, it has been reported that some HDPs are inac-
tivated by physiological concentrations of salt and cations when
tested in vitro and that the physiological concentrations of HDPs
are far lower than those required to exert antimicrobial activ-
ity in vitro (Yang et al., 2002; Boman, 2003; Bowdish et al.,
2005).
In addition to their bactericidal activity, accumulating evi-
dences are showing that HDPs also have a key modulatory
role in the innate immune response and are an important link
between the innate and adaptive immune responses under phys-
iological conditions (Zasloff, 2002). During a microbial inva-
sion, the macrophages and dendritic cells (DCs) of the innate
immune system detect the presence of microorganisms through
the recognition of specific pathogen-associated molecular pat-
terns (PAMPS) such as the gram-negative LPS endotoxin. An
early immune response is driven by the interaction between
cell receptors and the PAMPS, leading to the production of
potent pro-inflammatory cytokines such as IL-6, IL-12 and
TNF (Medzhitov, 2007). The production of these cytokines as
well as the up-regulation of co-stimulatory molecules on DCs,
macrophages, granulocytes and mast cells, are crucial points in
the establishment of a protective adaptive immune response.
However, an excessive inflammatory response can lead to sep-
sis, septic shock and also death (Castellheim et al., 2009; Giuliani
et al., 2010). HDPs are known to neutralize LPS-mediated
responses (Murakami et al., 2009; Giuliani et al., 2010). They
have affinity for LPS and can prevent lethal endotoxemia by sup-
pressing cytokine production by macrophages in the presence
of bacteria or other non-specific inflammatory stimuli (Gough
et al., 1996; Miles et al., 2009; Tecle et al., 2010). These pep-
tides also participate in the inflammatory response by acting
as chemotaxins for immune cells, including the recruitment of
neutrophils by an increase of IL-8 production, the mobilization
of immunocompetent T-cells and the enhancement of cellu-
lar adhesion and the subsequent cellular transepithelial migra-
tion (Chertov et al., 1996; Van Wetering et al., 1997; Hata and
Gallo, 2008). HDPs promote phagocytosis while inhibiting oxi-
dant responses of neutrophils or monocytes (Tecle et al., 2007;
Miles et al., 2009). They also stimulate wound healing and
angiogenesis through direct action on epithelial and endothelial
cell proliferation (Koczulla and Bals, 2003; Li et al., 2006; Otte
et al., 2008). Other activities of HDPs include the modulation
of pathways regulating cell survival and apoptosis in various
Frontiers in Immunology | Molecular Innate Immunity August 2012 | Volume 3 | Article 269 | 2
Cotton et al. Defense peptides secreted by helminth pathogens
cell types, the induction of chemokines and other immune
mediators (Scott et al., 2002; Tjabringa et al., 2003; Bowdish
et al., 2004; Mookherjee et al., 2006) and the stimulation of
leukocyte degranulation and other microbicidal activities. HDPs
have a unique ability to suppress hyperinflammatory responses
while maintaining protective effector functions of the immune
response.
FEATURES OF HELMINTH-INDUCED IMMUNE RESPONSES
Although each helminth pathogen triggers characteristic infec-
tions associated with the biology of the specific parasite, they
all evoke immune responses that share common patterns. The
first conserved feature of helminth infection is a T helper
(Th) 2-type dominated immune response. Th2-type immu-
nity is typically characterized by an increase in the levels
of interleukin-4 (IL-4) and other Th2-type cytokines (includ-
ing IL-5, IL-9, IL-13, and IL-21), activation and expansion of
CD4+ Th2 cells, plasma cells secreting immunoglobulin E (IgE),
eosinophils, mast cells, and basophils, all of which can pro-
duce various types of Th2-type cytokines (Jenkins et al., 2011).
The other recurring immunological characteristic of helminth
infection is the down regulation of the Th1-type and Th17-type
responses and their associated inflammation. Th1-type responses
are characterized with increases in the number of Th1 cells,
cytotoxic CD8+ T cells, neutrophils and macrophages. Various
cytokines that are expressed during Th2-type responses, includ-
ing IL-4, IL-13, and IL-21 can also downregulate Th1-type and
Th17-type.
A further important dimension in helminth infection is the
differentiation of alternatively activated macrophages (aaMϕs)
under the influence of Th2-type cytokines. While aaMϕs are
recruited to the site of infection and are implicated as functional
effectors, they also have strong anti-inflammatory properties and
highly express genes whose functions relate to the repair of
extracellular matrices, wound healing and fibrosis. The overall
outcome of a helminth infection may then be an environment
with down-regulated proinflammatory responsiveness, activated
damage repair mechanisms and a tightly controlled develop-
ment of Th2 anti-parasite effector responses (see Cook et al.,
2012).
Hence, helminth parasites are master regulators of immune
responses utilizing complex mechanisms to favor long-term per-
sistence in the host. Mechanistically, parasite modulation of the
immune system is likely to be effected through the release of
soluble mediators which ligate, degrade or otherwise interact
with host immune cells and molecules (Lightowlers and Rickard,
1988). Much of the earlier literature on immunological effects
of helminth products depended on crude extract (such as SEA
schistosome eggs antigen), although the degree to which the
host is exposed to constituent molecules was uncertain. While
both somatically derived and secreted products are known to
have immunological activity (Johnston et al., 2009), the secreted
helminth modulators are those most likely to be physiologi-
cal actors at the interface between live parasites and the host
(Hewitson et al., 2009). For that reason, research has focused
on identifying “excretory-secretory” (ES) products released by
live worms with immunomodulatory properties (for reviews on
the subject: Maizels and Yazdanbakhsh, 2003; Thomas and Harn,
2004; Dzik, 2006).
DEFENSE PEPTIDES SECRETED BY HELMINTH PATHOGENS
Prospecting of helminth ES products for molecules with
immunomodulatory effects has led us to the discovery of a novel
family of proteins, the HelminthDefenseMolecules (HDMs). The
HDMs were termed following their characterization: they exhibit
similar functional and biochemical properties to the human
defense peptides, defensins and cathelicidins. To date, the best
studied HDM is the 8 kDa protein (FhHDM-1) secreted by the
trematode, Fasciola hepatica, which causes liver fluke diseases in
animals and humans. FhHDM-1 can be grouped in the catheli-
cidin family as it has a high propensity to adopt α-helical sec-
ondary structure (Figure 1). In addition, similar to hCAP18, the
secreted FhHDM-1 undergoes cleavage by an endogenous pro-
tease (the major cysteine protease from F. hepatica, cathepsin L1)
to release a C-terminal fragment. The 34-residue C-terminal
peptide of FhHDM-1 contains a 21-residue amphipathic helix
which exhibits a marked structural parallel with the bioactive
human LL-37 peptide. The amphipathic helix of LL-37 anchors
the peptide to phospholipidmembranes through interaction with
hydrophobic face (Agerberth et al., 1995; Porcelli et al., 2008) and
is important for its antimicrobial activity (Giuliani et al., 2010).
The same amphipathic helix of the cathelicidin hCAP18-derived
peptide has also been suggested to be responsible for interacting
with LPS (Hoess et al., 1993; Porro, 1994). Like LL-37, the amphi-
pathic helix of the C-terminal peptide of FhHDM-1 binds E. coli
LPS; it is a key functional determinant necessary for its biologi-
cal properties (Robinson et al., 2011). Phylogenetic/bioinformatic
studies revealed that a family of related HDMs are expressed by
several major animal and human trematodes that inhabit var-
ious tissues of the host including the mesenteric blood vessels
(Schistosoma), the liver (Fasciola, Opisthorcis, Clonorchis) and
lungs (Paragonimus).
WHYWOULD PARASITES HAVE A NEED FOR DEFENSE
PEPTIDE?
It is well known that intestinal injury and systemic endotox-
emia are two factors leading to morbidity in helminth infected
mice (Herbert et al., 2004; Leeto et al., 2006). Loss of gut bar-
rier function and consequently the migration of luminal antigens
(bacteria and their toxic products) into the systemic circulation
are frequent in helminth infection. Accordingly, enteric nema-
tode infection is characterized by enhanced permeability of the
intestinal epithelium, primarily mediated by activated mast cells
(McDermott et al., 2003), which contributes to parasite rejection
but may lead to the translocation of bacterial LPS into the por-
tal circulation (Farid et al., 2008). The same phenomena can be
observed in non-enteric worms. For instance, both Schistosoma
mansoni (a trematode that resides in the mesenteric vein) and
F. hepatica (a trematode that lives in the bile ducts) cause dam-
ages leading to the systemic movement of bacteria (Ogunrinade
and Adegoke, 1982; Herbert et al., 2004; Ferraz et al., 2005;
Valero et al., 2006). Despite this translocation of enteric microbes,
fatal endotoxemia during infection with trematodes is not a fre-
quent situation (Onguru et al., 2011). Additionally, in endemic
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FIGURE 1 | (A) Primary amino acid sequence of the archetypal HDMsecreted
by Fasciola hepatica, FhHDM-1.TheN-terminal signal peptide is shown in italics
and the predicted secondary structure (predominantly alpha helix) is shown
below. (B)Model structure of FhHDM-1with the residues forming the
hydrophobic faceof themolecule shown in red. (C)Helicalwheel analysis shows
that the C-terminal region of FhHDM-1 forms a distinct amphipathic helix.
areas for helminth parasites, co-infection with gram-negative
bacteria, most commonly Salmonella sp, is frequent (Melhem
and Loverde, 1984). The mechanisms of resistance to septi-
caemia during helminth infection are not fully understood.
One explanation proposed by Robinson et al. (2011) is that
the active secretion of HDM by parasites during their lifes-
pan in the mammalian host ensures that potentially lethal LPS,
either from intestinal flora or from microbial co-infections, is
neutralised and that LPS-mediated activation of macrophages
is controlled. In fact, bacterial LPS is known to be a key
molecule in the pathogenesis of endotoxin shock associated
with gram-negative bacterial infections (Lehmann et al., 1987;
Morrison et al., 1994; Castellheim et al., 2009). As mentioned
in Section “Structural characteristics and properties of HDPs,”
LL-37 neutralises the biological activities of LPS by binding
to the microbial molecule (Kirikae et al., 1998). The trans-
fer of LPS to cellular CD14 by serum LPS-binding protein
(LBP) is the first event in the recognition of microbial infec-
tion. This bimolecular complex then initiates downstream sig-
naling via interaction with cellular TLRs (Beutler et al., 2003),
which results in the secretion of inflammatory mediators. Just
like human LL-37, the direct binding of FhHDM-1 to LPS
blocks the interaction of LPS with LBP, thus reducing the num-
ber of LPS molecules that are targeted to the TLR signaling
complex on the macrophage cell surface. This in turn prevents
LPS-induced activation of macrophages. Therefore, FhHDM-1
impairs LPS signaling and protect against harmful immune
responses by reducing the release of inflammatory mediators
from macrophages.
CONCLUSION
HDPs are an evolutionarily conserved component of the innate
immune response and are found among all classes of life. They
have been demonstrated to possess antimicrobial activities on a
broad range of organism, killing Gram negative and Gram pos-
itive bacteria, mycobacteria, enveloped viruses, fungi and even
transformed or cancerous cells. It also appears that HDPs have
the ability to enhance immunity by functioning as immunomod-
ulators. The discovery of a family of defense peptides that is con-
served amongst medically-important trematode pathogens has
raised the question of their utility for helminths.Whywould para-
sitic worms need HDPs? Helminth parasites are master regulators
of immune responses in order to ensure life-long persistence
in the host. One strategy of immune regulation is the secre-
tion of a wide range of immunoregulatory molecules, which
are able to target various host cells and alter them to induce a
highly directed host response known as a “modified Th2-type
response.” Our recent finding of a family of HDMs that modulate
the immune response via molecular mimicry of HDPs provides
a common mechanism for the anti-inflammatory properties of
helminth infection (Robinson et al., 2011). By targeting key stages
in LPS-mediated cell signaling, the helminth parasite prevents the
activation of innate immune response and enhances its longevity
by increasing the survival of the host.
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